Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · Real-Time Price · USD
43.30
+2.61 (6.41%)
At close: Sep 3, 2025, 4:00 PM
43.00
-0.30 (-0.69%)
Pre-market: Sep 4, 2025, 8:29 AM EDT
6.41%
Market Cap3.10B
Revenue (ttm)44.71M
Net Income (ttm)-275.43M
Shares Out 71.50M
EPS (ttm)-3.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume789,339
Open40.37
Previous Close40.69
Day's Range40.10 - 43.43
52-Week Range19.45 - 53.27
Beta2.18
AnalystsStrong Buy
Price Target58.53 (+35.17%)
Earnings DateOct 30, 2025

About KYMR

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat aut... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 188
Stock Exchange NASDAQ
Ticker Symbol KYMR
Full Company Profile

Financial Performance

In 2024, Kymera Therapeutics's revenue was $47.07 million, a decrease of -40.11% compared to the previous year's $78.59 million. Losses were -$223.86 million, 52.3% more than in 2023.

Financial Statements

Analyst Summary

According to 15 analysts, the average rating for KYMR stock is "Strong Buy." The 12-month stock price target is $58.53, which is an increase of 35.17% from the latest price.

Price Target
$58.53
(35.17% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Citi's 2025 Biopharma Back to School Conference September 3, 2025 10:30 AM EDT Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Jare...

19 hours ago - Seeking Alpha

Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...

1 day ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

8 days ago - GlobeNewsWire

The Best Small-Cap Stocks to Buy Now

Wall Street's best small-cap stocks to buy include biotech, real estate and software names.

Other symbols: DNLIWAY
22 days ago - Kiplinger

Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Conference Call August 11, 2025 8:30 AM ET Company Participants Bruce N. Jacobs - Chief Financial Officer Jared A.

23 days ago - Seeking Alpha

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile

24 days ago - GlobeNewsWire

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

2 months ago - GlobeNewsWire

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines...

2 months ago - GlobeNewsWire

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.

Other symbols: GILD
2 months ago - Reuters

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474

2 months ago - GlobeNewsWire

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive opt...

Other symbols: GILD
2 months ago - Business Wire

Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial

Shares of the biotech Kymera Therapeutics are up 50% since Monday.

3 months ago - Barrons

Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data

Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using...

3 months ago - Seeking Alpha

Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

Its dermatitis drug could win at least 10% of annual sales in dermatitis by 2030—or about $3 billion.

3 months ago - Barrons

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile

3 months ago - GlobeNewsWire

Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025 Company to host video webcast at 8:00 a.m. ET on Monday, June 2, 2025

3 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

3 months ago - GlobeNewsWire

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression

3 months ago - GlobeNewsWire

Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff

I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protei...

4 months ago - Seeking Alpha

Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Found...

4 months ago - Seeking Alpha

Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug

4 months ago - GlobeNewsWire

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermati...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

4 months ago - GlobeNewsWire

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June ...

4 months ago - GlobeNewsWire

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicine...

5 months ago - GlobeNewsWire